Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size

Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung Carcinoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2010 by Stanford University.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
TRDRP
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00568906
First received: December 4, 2007
Last updated: July 2, 2010
Last verified: July 2010
History of Changes
  Purpose
This study will investigate gene expression profiles in normal human lung tissue, lung carcinoma and metastatic tumor to the lung. The expression of up to 20,000 genes in a given lung tissue sample will be examined by cDNA microarray analysis and compared to normal lung tissue. In addition, we hope to identify a particular subset of lung cancer cells with an enhanced capacity for proliferation and self-renewal , analogous to the stem cells recently identified for certain types of leukemia, breast cancer and brain tumors.

Condition
Carcinoma, Giant Cell
Carcinoma, Non-Small-Cell Lung
Lung Cancer

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung Carcinoma

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Stanford University:

Biospecimen Retention:   Samples With DNA
Lung tissue or pleural fluid.

Estimated Enrollment: 150
Study Start Date: February 2002
Estimated Study Completion Date: June 2011
Estimated Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
  Eligibility
Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who agree to participate in this study will be those who are undergoing wedge resection, lobectomy on pneumonectomy for clinically diagnosed lung carcinoma or metastatic tumors to the lung, or who are undergoing therapeutic or diagnostic thoracentesis for malignant pleural effusion.
Criteria

Inclusion Criteria:Adults with non small cell lung cancer

Exclusion Criteria:NA

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00568906

Contacts
Contact: Susan Jacobs, RN (650) 725-8082 ssjpulm@stanford.edu

Locations
United States, California
Stanford University School of Medicine Recruiting
Stanford, California, United States, 94305
Contact: Susan Jacobs, RN    650-725-8082    ssjpulm@stanford.edu   
Contact: Cancer Clinical Trials Office    (650) 498-7061      
Principal Investigator: Glenn D. Rosen         
Sub-Investigator: Laurie Elizabeth Ailles         
Sub-Investigator: Walter B Cannon         
Sub-Investigator: Dr Jessica S. Donington         
Sub-Investigator: Cathy Shachaf         
Sub-Investigator: Heather A. Wakelee         
Sub-Investigator: Irving L. Weissman M.D.         
Sub-Investigator: Richard I Whyte         
Sub-Investigator: Tze-Ming Chen         
Principal Investigator: Daya Upadhyay         
Sponsors and Collaborators
Stanford University
TRDRP
Investigators
Principal Investigator: Daya Upadhyay Stanford University
Principal Investigator: Glenn D. Rosen Stanford University
  More Information

Responsible Party: Glenn D. Rosen, Stanford University School of Medicine
ClinicalTrials.gov Identifier: NCT00568906     History of Changes
Other Study ID Numbers: SU-11062007-807  76094  LUN0011 
Study First Received: December 4, 2007
Last Updated: July 2, 2010
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Carcinoma
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Giant Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
 Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms

ClinicalTrials.gov processed this record on September 27, 2016